HDAC2 and hematologic disorder: HDACs can regulate oncogene and tumor suppressor gene activities, which thereby play a vital part in tumorigenesis.29 HDACs are usually investigated in the preclinical studies on hematological malignancies and solid tumors such as the IM-resistant CML.29,30 In the current work, CAY10683, the new selective HDAC2 inhibitor, was utilized in combination with IM for treating hematological disorders for the first time.